Trial reportThrombosis and haemostasis2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Trial report in Thrombosis and haemostasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02555878 (Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.The Cochrane database of systematic reviews · 2020Pooled it
- Effects of ulinastatin therapy in deep vein thrombosis prevention after brain tumor surgery: A single-center randomized controlled trial.World journal of clinical cases · 2023Trial
- Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI.Blood advances · 2022Trial
- Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.Cancer medicine · 2020Trial
- Intravenous thrombolysis in the context of stroke and cancer.Journal of thrombosis and thrombolysis · 2025Review
- Article
- Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study.Blood advances · 2023Article
- Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care.Cancers · 2023Review
- Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy.Thrombosis journal · 2023Article
- The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.Journal of thrombosis and haemostasis : JTH · 2022Article
- Tumor-expressed microRNAs associated with venous thromboembolism in colorectal cancer.Research and practice in thrombosis and haemostasis · 2022Article
- [What the (general and abdominal) surgeon should know about thrombosis prophylaxis].Chirurgie (Heidelberg, Germany) · 2022Review
- Predictive models for thromboembolic events in giant cell arteritis: A US veterans health administration population-based study.Frontiers in immunology · 2022Article
- A risk prediction model for evaluating thrombosis extension of muscle calf venous thrombosis after craniotomy.Frontiers in surgery · 2022Article
- Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial.Research and practice in thrombosis and haemostasis · 2021Article
- Treatment with a Direct Oral Anticoagulant for Nonbacterial Thrombotic Endocarditis.Internal medicine (Tokyo, Japan) · 2021Article
- Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies.International journal of general medicine · 2021Article
- Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice.Frontiers in pharmacology · 2021Review
- Concepts in cardiac oncology.European heart journal supplements : journal of the European Society of Cardiology · 2020Article
- Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 13 institutions in 4 countries.
Funding
Abstract
Venous thromboembolism (VTE) is a frequent complication of cancer associated with morbidity, mortality, increased hospitalizations and higher health care costs. Cancer patients at increased risk for VTE can be identified using a validated risk assessment score, and the incidence of VTE can be reduced in high-risk settings using anticoagulation. Rivaroxaban is a potent, oral, direct, factor Xa inhibitor approved for the prevention and treatment of thromboembolic events, including VTE. CASSINI is a double-blind, randomized, parallel-group, multicentre study comparing rivaroxaban with placebo in adult ambulatory patients with various cancers who are initiating systemic cancer therapy and are at high risk of VTE (Khorana score ≥ 2). Patients with primary brain tumours or those at risk for bleeding are excluded. Approximately 700 patients will be randomized 1:1 to rivaroxaban 10 mg daily or placebo for up to 6 months if there is no evidence of VTE from compression ultrasonography (CU) during screening or from routine care imaging within 30 days prior to randomization. Mandatory CU will also be performed at weeks 8 and 16 (±7 days), and at study end (±3 days). The primary efficacy hypothesis is that anticoagulation with rivaroxaban reduces the composite of objectively confirmed symptomatic or asymptomatic, lower-extremity, proximal deep-vein thrombosis (DVT); symptomatic, upper-extremity DVT; symptomatic or incidental pulmonary embolism; and VTE-related death compared with placebo. The primary safety objective is to assess major bleeding events (Clinical trial information: NCT02555878).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.